4-formylphenyl phosphorodichloridate | 99281-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-formylphenyl phosphorodichloridate
• 英文别名: 4-Dichlorophosphoryloxybenzaldehyde
• CAS: 99281-10-4
• 化学式: C₇H₅Cl₂O₃P
• 分子量: 238.995
• InChiKey: GJYVMWPZASOZIU-UHFFFAOYSA-N

物化性质

• 沸点：
  319.0±25.0 °C(Predicted)
• 密度：
  1.536±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-formylphenyl phosphorodichloridate 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 二氯甲烷-D2 为溶剂， 反应 40.0h， 生成
  参考文献：
  名称：

  A Metathesis Route for BODIPY Labeled Polyolefins

  摘要：

  It is demonstrated how acyclic diene metathesis polymerization (ADMET) provides an efficient strategy for the labeling of polyolefins. The versatility of phosphorus chemistry allows designing substituted BODIPY monomers or chain stoppers for the synthesis of precise labeled (degradable) polyphosphoesters.

  DOI：

  10.1021/ol401461h
• 作为产物：
  描述：

  对羟基苯甲醛 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以7.8 g的产率得到4-formylphenyl phosphorodichloridate
  参考文献：
  名称：

  A Metathesis Route for BODIPY Labeled Polyolefins

  摘要：

  It is demonstrated how acyclic diene metathesis polymerization (ADMET) provides an efficient strategy for the labeling of polyolefins. The versatility of phosphorus chemistry allows designing substituted BODIPY monomers or chain stoppers for the synthesis of precise labeled (degradable) polyphosphoesters.

  DOI：

  10.1021/ol401461h

文献信息

• [EN] RELEASABLE ANTIBODY CONJUGATES<br/>[FR] CONJUGUÉS D'ANTICORPS LIBÉRABLES
  申请人：QUIAPEG PHARMACEUTICALS AB

  公开号：WO2019171358A1

  公开（公告）日：2019-09-12

  This document provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein D is a residue of a cytotoxic or chemotherapeutic compound, which undergoes hydrolysis under physiological conditions to release the cytotoxic or chemotherapeutic compound and which are useful in the treatment of cancer and other diseases.

  本文件提供了化合物的公式(I)，或其药用盐，其中D是细胞毒性或化疗化合物的残基，该残基在生理条件下水解释放出细胞毒性或化疗化合物，并且在癌症和其他疾病的治疗中是有用的。
• RELEASABLE GLP-1 CONJUGATES
  申请人：QuiaPEG Pharmaceuticals AB

  公开号：US20200108124A1

  公开（公告）日：2020-04-09

  The present application provides compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP-polypeptide or an analog thereof, which underdo hydrolysis under physiological conditions to release the GLP-polypeptide or analog thereof and which are useful in the treatment of disorders that could be beneficially treated with the GLP-polypeptide or analog thereof.

  本申请提供了化合物的化学式(I)或其药用盐，其中D是GLP-多肽或其类似物的残基，它们在生理条件下经水解释放GLP-多肽或其类似物，并且对需要使用GLP-多肽或其类似物治疗的疾病具有益处。
• Releasable GLP-1 conjugates
  申请人：QuiaPEG Pharmaceuticals AB

  公开号：US11357828B2

  公开（公告）日：2022-06-14

  The present application provides compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP-polypeptide or an analog thereof, which underdo hydrolysis under physiological conditions to release the GLP-polypeptide or analog thereof and which are useful in the treatment of disorders that could be beneficially treated with the GLP-polypeptide or analog thereof.

  本申请提供了式 (I) 化合物： 或其药学上可接受的盐，其中 D 是 GLP 多肽或其类似物的残基，在生理条件下可水解释放出 GLP 多肽或其类似物，可用于治疗可使用 GLP 多肽或其类似物进行有益治疗的疾病。
• Novel phosphoramidates with porphine and nitrogenous drug: One-pot synthesis and orientation to cancer cells
  作者：Zhi-Wei Wang、Can-Cheng Guo、Wen-Zhong Xie、Chao-Zhou Liu、Chun-Guang Xiao、Ze Tan

  DOI：10.1016/j.ejmech.2009.11.027

  日期：2010.3

  One-pot synthesis of novel phosphoramidates with porphine and nitrogenous drug was accomplished. In the absence of light, MTT test showed that they killed the BEL-7402 liver cancer cells effectively in vitro. The cell viability studied on normal liver and cancer cells showed that porphine phosphoramidates selectively kill the cancer cells, which was in sharp contrast with the non-porphine containing compound 4-formylphenyl N,N-bis(2-chloroethyl)-phosphoramidate. These results, coupled with the cell uptake test showing that they could differentiate the tumor cells from the normal cells by their selective accumulation in cancer cells, gave strong support to the notion that the introduction of porphine moiety in these molecules was responsible for the effectiveness and cell differentiability of these porphine phosphoramidates. (C) 2009 Published by Elsevier Masson SAS.
• [EN] RELEASABLE GLP-1 CONJUGATES<br/>[FR] CONJUGUÉS DE GLP-1 LIBÉRABLES
  申请人：QUIAPEG PHARMACEUTICALS AB

  公开号：WO2020053815A1

  公开（公告）日：2020-03-19

  The present application provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP-polypeptide or an analog thereof, which underdo hydrolysis under physiological conditions to release the GLP-polypeptide or analog thereof and which are useful in the treatment of disorders that could be beneficially treated with the GLP-polypeptide or analog thereof.